Sanara MedTech Partners with InfuSystem for Innovative Cancer Solution

Sanara MedTech and InfuSystem Join Forces for Oncology Patients

In a strategic move, Sanara MedTech Inc. has announced a partnership with InfuSystem Holdings, Inc. to tackle a significant issue faced by cancer patients undergoing chemotherapy: oral mucositis. This debilitating condition causes painful mouth ulcers, adversely affecting the quality of life for hundreds of thousands of patients each year.

Exclusive Distribution Agreement with ChemoMouthpiece

Through this partnership, Sanara MedTech has executed an exclusive distribution agreement with ChemoMouthpiece, LLC, enhancing its commitment to improving clinical outcomes. ChemoMouthpiece has developed an innovative oral cryotherapy device aimed at reducing the incidence and severity of oral mucositis, which has received FDA 510(k) clearance for clinical application.

Addressing a Vital Need

Ron Nixon, the CEO of Sanara, emphasizes the importance of this partnership. "ChemoMouthpiece's clinically validated product presents a much-needed relief option for oncology patients plagued by oral mucositis. With the American Medical Association recently issuing a CPT code effective July 2024, there is potential for broader reimbursement accessibility for this critical therapy," he stated. This alignment complements Sanara’s broader skincare strategy, including proprietary collagen products that target other side effects of cancer treatments.

Strategic Overview of the Agreement

The distribution agreement means that SI Healthcare Technologies, a joint venture between Sanara and InfuSystem, will be the exclusive distributor of ChemoMouthpiece kits throughout the United States. This company plans to leverage InfuSystem’s established network, which serves approximately 3,000 cancer centers. By utilizing InfuSystem’s well-trained sales team, they aim to enhance the market reach and availability of the Chemo Mouthpiece.

Investing in Innovation

In addition to the distribution agreement, Sanara has made a significant investment of $5 million for a 6.6% stake in ChemoMouthpiece. This strategic investment underscores Sanara’s commitment to advancing technologies aimed at reducing healthcare costs while improving patient care.

Potential Market Impact

Oral mucositis is an expensive complication of cancer therapy, affecting an estimated 500,000 to 1 million patients annually in the U.S. The financial implications for healthcare providers are substantial, with the market for oral mucositis products exceeding $600 million. SI Technologies believes that their product could provide significant cost reductions in oncology treatment settings, thereby enhancing patient quality of life and allowing for uninterrupted cancer treatments.

Expert Testimonials

Richard Dilorio, CEO of InfuSystem, expressed optimism about the partnership, stating that their combined expertise would enable them to deliver effective solutions to patients. "Our collaboration with Sanara aims to provide effective oral cryotherapy options to ease the suffering of those battling cancer," he stated. Similarly, David Yoskowitz, President and CEO of ChemoMouthpiece, highlighted the established reputation of SI Technologies in the oncology space as a key factor in their partnership. He stated, "We anticipate this collaboration will facilitate the uptake of the Chemo Mouthpiece among oncologists, maximizing its potential impact on patient care."

About ChemoMouthpiece, LLC

ChemoMouthpiece is dedicated to developing clinical solutions for oral mucositis based on firsthand experiences that led to innovative changes in treatment approaches. Their flagship product, the Chemo Mouthpiece, was born from a personal struggle with oral mucositis and seeks to offer patients reliable relief by cooling the oral cavity effectively.

About Sanara MedTech and InfuSystem

Sanara MedTech is focused on revolutionary technologies in various healthcare sectors, concentrating on improving clinical outcomes while reducing costs for healthcare providers. Meanwhile, InfuSystem serves as an essential partner in the health care industry, facilitating outpatient services with a two-pronged business model that enhances patient care. Their collaborative efforts underscore a robust dedication to facilitating health outcomes for those in need.

Investor Contact:

Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com

Frequently Asked Questions

1. What is the Chemo Mouthpiece?

The Chemo Mouthpiece is an oral cryotherapy device designed to alleviate oral mucositis in cancer patients undergoing chemotherapy.

2. How does the partnership benefit oncology patients?

The partnership enhances product distribution, improving patient access to effective relief from the impacts of oral mucositis.

3. What is oral mucositis and why is it significant?

Oral mucositis is a painful complication of cancer treatment that negatively affects patients’ quality of life, and it affects hundreds of thousands of individuals annually.

4. What companies are involved in this agreement?

Sanara MedTech Inc., InfuSystem Holdings, Inc., and ChemoMouthpiece, LLC are the key players in this partnership.

5. How much has Sanara invested in ChemoMouthpiece?

Sanara has invested $5 million for a 6.6% ownership stake in ChemoMouthpiece.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.